Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Britain Courts Anthropic Amid US Defense Department Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
LONDON, Aug. 01, 2017 -- Verona Pharma plc (AIM:VRP) (NASDAQ:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces today that Jan-Anders Karlsson, PhD, CEO of Verona Pharma, is scheduled to present at the 2017 Wedbush PacGrow Healthcare Conference.
An audio webcast of the presentation will be available on the Investors section of the company website, www.veronapharma.com. A replay of the webcast will be made available for 90 days following the presentation.
Event: Wedbush PacGrow Healthcare Conference
Date: August 15, 2017
Time: 3:05 PM EDT
Location: New York, NY
About Verona Pharma plc
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
Verona Pharma’s product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF), and potentially asthma.
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 | |||
| Jan-Anders Karlsson, Chief Executive Officer | [email protected] | |||
| N+1 Singer (Nominated Adviser and UK Broker) | Tel: +44 (0)20 7496 3000 | |||
| Aubrey Powell / James White | ||||
| FTI Consulting (UK Media and Investor enquiries) | Tel: +44 (0)20 3727 1000 | |||
| Simon Conway / Stephanie Cuthbert / Natalie Garland-Collins | [email protected] | |||
| ICR, Inc. (US Media and Investor enquiries) | ||||
| James Heins | Tel: +1 203-682-8251 [email protected] | |||
| Stephanie Carrington | Tel. +1 646-277-1282 [email protected] |
